Quantitative expression evaluation of PRAME gene in osteosarcoma.

Autor: Kuruwitage Ishikawa AS; Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Sao Paulo, SP, Brazil., Tesser-Gamba F; Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Sao Paulo, SP, Brazil.; Department of Morphology and Genetics, Federal University of Sao Paulo, Sao Paulo, SP, Brazil., Petrilli AS; Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Sao Paulo, SP, Brazil.; Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, SP, Brazil., de Seixas-Alves MT; Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Sao Paulo, SP, Brazil.; Department of Pathology, Federal University of Sao Paulo, Sao Paulo, SP, Brazil., Garcia-Filho RJ; Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Sao Paulo, SP, Brazil.; Department of Orthopedic Surgery and Traumatology, Federal University of Sao Paulo, Sao Paulo, SP, Brazil., de Toledo SRC; Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo, Sao Paulo, SP, Brazil. silviatoledo@graacc.org.br.; Department of Morphology and Genetics, Federal University of Sao Paulo, Sao Paulo, SP, Brazil. silviatoledo@graacc.org.br.
Jazyk: angličtina
Zdroj: Molecular biology reports [Mol Biol Rep] 2023 May; Vol. 50 (5), pp. 4301-4307. Date of Electronic Publication: 2023 Mar 15.
DOI: 10.1007/s11033-023-08290-y
Abstrakt: Background: In a previous study, our group observed that 68% of the osteosarcoma (OS) samples presented PRAME (Preferentially Expressed Antigen in Melanoma) gene expression. In this work, we propose to investigate quantitatively gene expression of PRAME in distinct patients groups.
Methods and Results: 61 osteosarcoma samples, from 3 distinct patients groups were selected for this study: (1) Patients younger than 10 years old at diagnosis, (2) Patients that had poor evolution of disease and (3) Patients that were in remission of disease and had treatment with no intercurrences) PRAME gene expression levels were obtained using quantitative Real-Time Polymerase Chain Reaction method (qRT-PCR). Clinical parameters were collected from patient's medical charts. Results demonstrated an increase in PRAME gene expression in all samples, with high variation in expression levels, when considering all samples and when analyzed in each group. In addition, no statistical difference was found when considering clinical data collected or patients groups.
Conclusion: PRAME gene expression quantitative investigation did not bring any complementary information beyond of what had already been observed in other qualitative investigations published by our group, there is no relation between PRAME gene expression levels and disease evolution. However, the findings in this work contribute for validation PRAME gene expression as a good biomarker to OS, which, in the future, may allow identification circulating tumor cell or molecules to contribute with early diagnostic of metastasis, a genuine problem in OS that determinate flattening in survival curves.
(© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: